James Molloy joins equity research team at A.G.P./Alliance


James Molloy has joined A.G.P./Alliance Global Partners as a managing director and biotechnology and specialty pharmaceuticals equity research analyst.

He will provide coverage of companies in several therapeutic categories, with a focus on immuno-oncology, central nervous system, cardiovascular, and anti-infective disorders. 

Mr. Molloy has almost two decades of experience as a senior analyst covering both the mid-capitalization and emerging biotechnology and pharmaceutical sectors.

Prior to joining A.G.P., he was a managing director, biotechnology and specialty pharmaceuticals equity research analyst at Laidlaw Capital Markets, Janney Montgomery Scott and ThinkEquity Partners, and a VP of equity research at Oppenheimer. 

In a statement, A.G.P. executive chairman, Phil Michals, said Mr. Molly “really understands this highly complex and constantly evolving space, and he has great relationships in the industry.”

Sydney Stewart